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ABSTRACT
Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer.
Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that
bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment
of schizophrenia and angina respectively, inhibit Akt-pS473 phosphorylation and
promote FOXO3 nuclear localization and activation in TNBC cells. BPD and TFP inhibit
survival and proliferation in TNBC cells and suppress the growth of TNBC tumors,
whereas silencing FOXO3 reduces the BPD- and TFP-mediated suppression of survival
in TNBC cells. While BPD and TFP decrease the expression of oncogenic c-Myc, KLF5,
and dopamine receptor DRD2 in TNBC cells, silencing FOXO3 diminishes BPD- and TFPmediated repression of the expression of these proteins in TNBC cells. Since c-Myc,
KLF5, and DRD2 have been suggested to increase cancer stem cell-like populations
in various tumors, reducing these proteins in response to BPD and TFP suggests a
novel FOXO3-dependent mechanism underlying BPD- and TFP-induced apoptosis in
TNBC cells.

INTRODUCTION

this disease. Although recent clinical investigations of
agents such as poly(ADP-ribose) polymerase (PARP)
inhibitors or EGFR inhibitors have emerged, outcomes from
recent clinical trials have been rather disappointing, with
substantially less clinical effectiveness detected than was
expected based on preclinical and early phase trials [8–10].
It is crucial to develop novel targeted therapeutic drugs.
FOXO3 is a key protein that controls the
transcription of a number of genes crucial for regulating
cell cycle control [11], DNA damage and stress responses
[12–15], aging and longevity [12, 16], cellular apoptosis
[12, 17–19], and suppression of cancer [20–23] in animal
and human cells; gene knockout findings reveal FOXO3’s
additional functions in tumor suppression [24] and the
maintenance of the hematopoietic stem cell pool [25].
While multiple mechanisms have been shown to regulate
FOXO3 activity, phosphorylation inhibits FOXO3

Breast cancer (BCa) is the most common cancer
in women worldwide, with nearly 1.7 million new cases
diagnosed and more than 520,000 related deaths in 2012
[1]. Many patients with advanced BCa will eventually
have a recurrence, often with the loss of chemo-sensitivity
and a poor prognosis [2–4]. Triple-negative breast cancers
(TNBCs) are defined by the absence of expression of
estrogen and progesterone receptors and HER2 receptors,
and they account for approximately 15% of all breast
cancers [5, 6]. However, TNBC has a much higher rate of
mortality than non-TNBC breast cancers because treatment
of this aggressive form of cancer is limited to conventional
chemotherapy [7]. Currently TNBCs still have no effective
targeted therapy; thus, there is clearly an unmet medical
need to find new effective targeted therapeutic drugs for

www.impactjournals.com/oncotarget

42110

Oncotarget

RESULTS

nuclear translocation that controls its regulation and
function. In proliferating cancer cells, survival signals
trigger PI3K to activate Akt which in turn phosphorylates
and inhibits specific pro-apoptotic targets such as Bad,
caspase-9, and FOXO3 [12, 17]. Consequently, loss of
function of FOXO3 has been linked to tumorigenesis and
poor patient survival in breast cancer [20, 22, 23] and
other cancers such as lung cancer [26], prostate cancer
[27], and ovarian cancer [28]. In the absence of survival
signal stimulation, the Akt pathway is inactivated and
its cellular targets such as FOXO3 can translocate to the
nucleus and induce the expression of cell cycle regulators
(e.g., p27Kip1) that lead to cell cycle arrest, or upregulate
certain genes (e.g., Fas-ligand and Bim) that result in
apoptosis depending on the physiological conditions
and the cell types [11, 12, 17–19]. The nuclear exclusion
and translocation of FOXO3 into the cytoplasm inhibits
FOXO3-dependent transcription. These findings suggest
that FOXO3 is a pivotal tumor suppressor, and the
regulation of FOXO3 activation in cancer cells may be a
promising approach for developing anticancer therapeutic
drugs. The identification of novel small molecules that
can promote the activity of FOXO3 in TNBC cells
can provide leads for new TNBC therapeutics against
malignant breast tumors in which the PI3K/Akt and/or
IKK/NF-kB signaling pathways are aberrantly activated,
and these molecules may also result in safe and effective
targeted therapy of TNBC.
In this study, we develop a new breast cancer cellbased enzymatic assay as the output to identify smallmolecule drugs that increase the activity of FOXO3 by
screening a druggable library of known compounds
that have been approved by the Food and Drug
Administration (FDA) because it has been suggested that
the most fruitful basis for the discovery of a new drug is to
seek new uses for old drugs [29]. Here we show anticancer
properties and the preclinical therapeutic effects of two
representative FDA-approved small-molecule drugs,
bepridil (BPD) and trifluoperazine (TFP), which have been
used clinically for treatment of schizophrenia and angina,
respectively [30, 31].
Both TFP and BPD show potent cytotoxic activity
in TNBC cells in culture and exhibit antitumor activity
in TNBC in vivo models. Activation of FOXO3 tumor
suppressor by TFP or BPD is a significant distinction
from traditional antipsychotic inhibitors and the resultant
downregulation of oncogenic survival factors, c-Myc
[32] and Kruppel-like factor 5 (KLF5) [33], in TNBC
is an interesting anticancer mechanism. Unexpectedly,
we uncover that both TFP and BPD display suppression
of the expression of the dopamine receptor D2 (DRD2),
which has been suggested as a key receptor for selectivetargeting cancer stem cells (CSC) [34], in a FOXO3dependent manner. This novel finding may broaden the
potential therapeutic applications beyond TNBC tumors,
which are enriched with CSC characteristics.
www.impactjournals.com/oncotarget

Identification and validation of FDA-approved
FOXO3-activating small-molecule drugs
To identify small molecules that can induce
the activity of FOXO3 in BCa cells, we developed a
new BCa cell-based enzymatic (ELISA) assay as the
output to identify small molecules that can significantly
inhibit the phosphorylation of Serine (S)-318/321 of
FOXO3 (FOXO3-pS318/321), which is primarily
localized in the cytoplasm of cells. Decreasing the level
of phospho-FOXO3 leads to an increase of FOXO3
nuclear localization and its activity in BCa cells. The
screening method is depicted in Figure 1A. To expedite
the future clinical trials for novel lead small-molecule
compounds, we screened 640 small-molecule drugs from
a commercially available FDA-approved small-molecule
library with this ELISA assay using a specific antibody
against FOXO3-pS318/321. We used LY294002 and
Wortmanin (the Akt inhibitors) as positive (inhibition)
controls and DMSO as negative control. A representative
screening result of our primary screen with these drugs
(20 µg/ml) in MCF7 cells is shown in Figure 1B. After
the primary screen, we initially selected 19 candidate
small-molecule compounds for further confirmation by
carrying out the secondary screen with two different BCa
cell lines (MDA-MB-231 and MCF7). In total, twelve
candidate compounds were confirmed, which showed
a decrease of the level of FOXO3-pS318/321 around
50% in each cell line as compared with negative control
(DMSO) (Figure 1C). Among them, seven top-ranked
compounds were selected, which showed a decrease
of the level of FOXO3-pS318/321 greater than 50% in
both BCa cell lines as compared with negative control,
after our secondary screens. The structures, original
clinical applications, and their identification numbers
corresponding to the results in Figure 1C are exhibited in
Figure 1D. While these 7 drugs have no common chemical
structure, two of them (BPD and TFP) have been shown
to target the same protein, calmodulin, and both of them
have been clinically applied to the same disorder as
antipsychotic drugs [30, 31]. Thus, we focused on these
two drugs for further studies.

TFP and BPD induce nuclear localization and
activating of FOXO3 in TNBC cells
To determine whether the treatment of TFP and
BPD can increase the expression level of FOXO3 and its
transcriptional activity, we treated TNBC MDA-MB-231
and BT549 cells with various doses of TFP or BPD for
24 hours and performed immunoblotting experiments
with total lysates of these drug-treated cells. Our data
show that TFP or BPD treatment leads to significant
upregulation of the expression of FOXO3 and p27Kip1
42111
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Figure 1: Primary and secondary screens of small-molecule drugs using a cell-based ELISA assay. (A) Schematic diagram
depicts the cell-based ELISA assay used for our drug screening. (B) One representative outcome of our cell-based ELISA assay is shown.
In principle, breast cancer cells (e.g., MDA-MB-231) were seeded in a 96-well tissue culture plate. The cells were fixed after various
treatments such as the small molecule library. After blocking, anti-phospho-FOXO3 specific antibody is incubated into the wells. The wells
were washed, followed by the addition of HRP-conjugated anti-IgG secondary antibody. The wells were washed again, a substrate solution
is added to the wells and color develops in proportion to the amount of protein. The Stop Solution changed the color from blue to yellow,
and the intensity of the color was measured at 450 nm. (C) Secondary screening results obtained from MDA-MB-231 and MCF7 cells are
shown. WT, Wortmanin. (D) The structures and original clinical applications of seven candidate compounds are shown.
www.impactjournals.com/oncotarget

42112

Oncotarget

and SOD2, transcriptional targets of FOXO3, in both
cell lines (Supplementary Figure S1). In addition, TFP or
BPD treatment significantly inhibits the phosphorylation
level of Akt-Serine 473 (Akt-pS473), a key kinase that
phosphorylates FOXO3, in both cell lines in a dosedependent manner. These results suggest that TFP or BPD
treatment can inhibit Akt activity, resulting in increasing
FOXO3 transcriptional activity.
To determine whether TFP or BPD treatment can
increase the nuclear translocation of FOXO3, we treated
MDA-MB-231 and BT549 cells with various doses of
TFP or BPD for 24 hours and performed immunoblotting
experiments with nuclear/cytoplasmic extracts from
these cells. Our data indicate that TFP or BPD treatment
increases the level of nuclear FOXO3 and the expression
of p27Kip1 in these cells in a dose-dependent manner
(Figure 2A–2B; Supplementary Figure S2) and in a timedependent manner (Supplementary Figures S3 and S4).
Meanwhile, these results are associated with a decrease
or no change of FOXO3 level in the cytoplasm of these
cells. We also treated BT549 cells with TFP or BPD or
control (DMSO) for 24 hours and analyzed the subcellular
localization of FOXO3 as well as the phosphorylation
of S-15 of p53 (p53-pS15), a hallmark of DNA damage
[35], in these cells using immuno-fluorescence analysis.
Our results showed that TFP or BPD promoted nuclear
localization of FOXO3 (i.e., activation of FOXO3) and
induced phosphorylation of p53-pS15 in BT549 cells
(Figure 2C), suggesting that TFP and BPD may induce
DNA damage and activate FOXO3 in TNBC cells.

and TFP treatments induced significant TUNEL-positive
cells, PARP-1 degradation, and an increase in the amount
of DNA fragmentation ~24 hours post drug treatments,
respectively (Figure 4B–4F; Supplementary Figure S6).
These results suggest that BPD and TFP may suppress cell
survival and promote apoptosis in TNBC cells.

BPD and TFP suppress the growth of TNBC
tumors in vivo
To determine if treatment with BPD and TFP can
suppress tumorigenesis or tumor growth in TNBC cells
in vivo, we injected MDA-MB-231 TNBC cells into
the flanks of female athymic nude mice. When palpable
solid tumors were detected, the tumor-bearing mice were
given an intravenous injection (0.1 ml) of BPD or TFP
[10 mg/kg-body weight/mouse] or the vehicle (DMSO,
negative control) three times per week at even intervals
for 5 weeks. The tumor volumes were measured twice per
week after the treatment. Our results show that BPD or
TFP significantly suppressed MDA-MB-231 TNBC tumor
growth in the mouse model (Figure 5).

Silencing FOXO3 potently decreases the TFP- or
BPD-mediated suppression of cell survival in
TNBC cells
Since it is known that FOXO3 can regulate cell
survival and proliferation (cycle control) [11] and that
activation of FOXO3 can promote cellular apoptosis
[12, 17–19], we sought to determine whether FOXO3
is necessary for regulating TFP- or BPD-mediated
inhibition of cell survival and proliferation in TNBC cells.
We silenced endogenous FOXO3 in BT549 and MDAMB-231 cells by transfecting these cells with FOXO3siRNA or Control-siRNA (Figure 6A, 6C). Then, we
treated these FOXO3-knockdown cells with TFP or BPD
or DMSO (negative control) to compare the effects of
these drugs on the rate of cell survival and proliferation
by using the colony formation assay. While TFP or BPD
treatment significantly suppressed the colony-forming
ability of BT549 and MDA-MB-231 cells, silencing
FOXO3 potently diminished the TFP- or BPD-mediated
suppression of cell survival in these cells (Figure 6B, 6D).
These results suggest that FOXO3 is essential for TFP and
BPD-mediated suppression of cell survival of TNBC cells.

BPD and TFP suppress cell survival and promote
cellular apoptosis in TNBC cells
To determine whether BPD and TFP treatments
suppress cell survival, we treated MDA-MB-231
and BT549 cells with various doses of BPD or TFP
or DMSO (control) for 72 hours, and performed cell
survival assays by the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assays. We found
that BPD and TFP treatments significantly suppressed
survival in these cells (Figure 3). To examine whether
BPD and TFP treatments induce apoptosis, we treated
MDA-MB-231 or BT549 cells with BPD or TFP and
analyzed apoptosis by standard flow cytometry analysis
with Annexin V staining, an indicator of apoptosis
[36]. We showed that BPD and TFP treatments induced
significant Annexin V-positive cell populations in a drug
dose-dependent manner (Figure 4A–4B; Supplementary
Figure S5). Moreover, we treated MDA-MB-231 or BT549
cells with various doses of TFP or BPD and analyzed
apoptosis by terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) apoptosis assays or
immunoblotting analysis of poly-ADP-ribose polymerase
(PARP) degradation, an indicator of apoptosis [37], assays
or DNA fragmentation assays. Our data showed that BPD
www.impactjournals.com/oncotarget

TFP and BPD significantly reduce the expression
of oncogenic c-Myc, KLF5, and DRD2 in TNBC
cells in a FOXO3-dependent manner
An important question in determining the
mechanism for suppressing cell survival is how TFP
and BPD contribute to the observed suppression of cell
survival or growth in TNBC cells. Because it has been
suggested that several cancer-promoting genes, such
42113
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Figure 2: TFP or BPD treatment significantly promotes nuclear translocation and activation of endogenous FOXO3 in
TNBC cells. (A–B) MDA-MB-231 cells were treated with a dose response of TFP (A) or BPD (B) or dimethylsulfoxide (DMSO) control
(denoted as 0 mM) for 24 hours, harvested, and fractionated for preparing cytoplasmic (Cyt.) and nuclear (Nuc.) extracts. Equal amount
of each fraction was analyzed by immunoblotting (IB) analysis with specific antibodies as indicated. β-actin and PARP1 represent the
fractionation and loading controls of the Cyt. and the Nuc. fractions, respectively. All these results shown above represented 3 independent
experiments. (C–D) BT549 cells were treated with control (DMSO) or TFP (5 mM) or BPD (5 mM) for 24 hours. The treated cells were
fixed and the subcellular localizations of endogenous FOXO3 and p53-pS15, a DNA damage marker, were detected using antibodies
against FOXO3 and p53-pS15 and followed by an Alexa Fluor 594 (red)- or Alexa Fluor 488(green)-conjugated secondary antibody, and
fluorescence microscopy. DAPI was used to show the nuclei, and co-localization of FOXO3 with p53-pS15 was shown as the merged
images (orange or yellow color).
www.impactjournals.com/oncotarget
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as Akt [38], c-Myc [32], KLF5 [33], and DRD2 [34]
are involved in cell survival or proliferation in BCa
cells, we sought to compare the status of these genes in
human TNBC tumors versus non-TNBC tumors. Thus,
we analyzed the gene amplification and mRNA copy
number gain (amplification/gain) data available from The
Cancer Genome Atlas (TCGA) datasets using cBioPortal
[39, 40]. As shown in Figure 7A and 7B, the Akt2 gene’s
amplification/gain alteration in 123 TNBC samples
(21%) is about 2-fold higher than that in 104 non-TNBC
samples (11%). The Akt3 and MYC genes’ amplification/
gain alterations are high (60%–71%) in both TNBC and
non-TNBC samples, while the Akt1 gene’s amplification/
gain alteration is low (6% and 9% in TNBC and nonTNBC samples, respectively) (not shown). Notably,
while the KLF5 gene’s amplification/gain alteration in
TNBC samples (12%) is 4-fold higher than that in nonTNBC samples (3%), the DRD2 gene’s amplification/gain
alteration in TNBC samples (11%) is 11-fold higher than
that in non-TNBC samples (1%).

To confirm that TFP or BPD treatment leads to
significant downregulation of the expression of key
oncogenic proteins in TNBC cells, we performed
immunoblotting experiments with nuclear/cytoplasmic
extracts from the drug-treated cells as described above.
Our data demonstrate that TFP or BPD treatment
significantly suppressed of the expression of oncogenic
c-Myc, KLF5, and DRD2 in BT549 cells (Figure 7C–7D).
As controls, our data also show that TFP or BPD treatment
potently increased the levels of FOXO3, p27Kip1,
g-H2AX, and p53-pS15 in BT549 cells, while TFP or
BPD treatment decreased the phosphorylation level of
Akt-pS473 as described above.
To confirm that FOXO3 is essential for regulating
the drug-mediated suppression of the expression of these
oncogenic proteins, we transfected BT549 cells with
FOXO3-siRNA or Control-siRNA (negative control)
and performed immunoblotting analysis with nuclear/
cytoplasmic extracts from the drug-treated cells as
described above. Our results show that the expression

Figure 3: The cytotoxic effect of TFP and BPD on human TNBC cells. The dose effects of TFP or BPD on cell viability of
MDA-MB-231 (A or C) and BT549 (B or D) cells were determined. Cells were cultured in a 96-well plate (2,000 cells/well), treated
with various doses of TFP or BPD as indicated, and incubated for 72 hours. The cell viability was determined by the MTT assay and the
relative cell survival rate percentage was calculated by dividing the optical density of each drug treatment by that of the control (DMSO)
treatment. Each data point represents the mean value from 3 independent experiments, with at least three replicates. The error bars represent
standard deviation by paired t-test. The significant P-values between the treatment group versus the control group are indicated (*P < 0.05,
**P < 0.01).
www.impactjournals.com/oncotarget
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Figure 4: BPD and TFP promote cellular apoptosis in TNBC cells. (A–B) MDA-MB-231 cells were treated with TFP or BPD

or DMSO (negative control) or camptothecin (CPT) (positive control) for 48 hours, harvested, and were subjected to Annexin V and
propidium iodide staining for determining apoptosis. (B) An average (%) of Annexin V-positive cells (apoptotic) cells was determined
and shown in the diagram. Each data point represents the mean value from 3 independent experiments. The error bars represent standard
deviation (SD). P values between the test-group treated with drugs versus the control-group treated with DMSO are shown. (C–E) MDAMB-231 cells were treated with TFP or BPD or DMSO for 48 hours, and the cells were fixed on the slides for determining apoptosis by
TUNEL assay. Nuclei were stained with DAPI (color-inverted to red), and merged images (yellow) were considered as apoptotic cells.
Scale bar: 20 mm. (D, E) An average (%) of apoptotic (TUNEL-positive) cells was determined and shown in the diagram. The samples
include three biological replicates. The error bars represent SD, and P values are shown. (F–G) MDA-MB-231 (F) or BT549 (G) cells were
treated with TFP or BPD or DMSO for 48 hours. Total lysates of cells were analyzed by Immunoblotting analysis with specific antibodies
against full-length PARP1 protein or cleaved PARP1 fragment (89 kDa) as indicated. β-actin represents the loading controls.
www.impactjournals.com/oncotarget
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of c-Myc, KLF5, and DRD2 in BT549-Control-siRNA
cells was downregulated significantly after TFP or BPD
treatment, whereas the drug-mediated downregulation
of the expression of c-Myc, KLF5, and DRD2 was
diminished in BT549-FOXO3-siRNA cells (Figure 8A).
Similarly, the drug-mediated increase of the levels of
FOXO3 and g-H2AX was diminished in BT549-FOXO3siRNA cells, while the levels of FOXO3 and g-H2AX in
BT549-Control-siRNA cells were increased significantly
after the drug treatment (Figure 8A). Taken together, these
results suggest that FOXO3 may be essential for TFP- or
BPD-mediated repression of the expression of c-Myc,
KLF5, and DRD2 in TNBC cells.

a shorter median time to relapse and death and does not
respond to endocrine therapy or other available targeted
agents at present. Increased aggressiveness of this tumor,
as well as resistance to standard drug therapies, may be
linked to the presence of CSC populations within TNBC
tumors. However, if anticancer therapies can eliminate
differentiated cancer cells but cannot overcome CSC
populations in TNBC tumors, a small population of tumorinitiating CSC may remain untouched and cause relapse in
the future. Thus, it is important to identify new therapeutic
drugs that can specifically target CSC populations in
tumors. Our results show that both TFP and BPD suppress
the expression of oncogenic c-Myc, KLF5, and DRD2
proteins, and silencing FOXO3 significantly diminishes
TFP- or BPD-mediated repression of the expression of
these proteins in TNBC cells. In addition to upregulation
of p27Kip1, activation of FOXO3 upregulates
pro-apoptotic Bax and Bim proteins [17, 19, 41]. Thus,
we have proposed a schematic representation of the
FOXO3-dependent promotion of apoptosis in TNBC cells
in response to the treatment of BPD or TFP (Figure 8B).

DISCUSSION
Here, we provide evidence that pharmacological
activation of FOXO3 by small-molecule drugs (TFP or
BPD) potently suppresses cell survival and proliferation
in TNBC cells in vitro and in TNBC tumors in vivo.
TNBC has been clinically proven to be associated with

Figure 5: BPD and TFP suppress the growth of TNBC tumors in the mouse tumor model. (A–B) MDA-MB-231 cells were

injected into female nude mice (n = 3/group). The tumor-bearing mice were given an i.v. injection of (A) BPD (10 mg/kg) or the vehicle
control (DMSO), and (B) TFP (10 mg/kg) or DMSO twice per week. The tumor volumes [(L × W2)/2] were measured. The results are
graphed as mean ± SEM numbers of tumor volumes. Significant P values are shown. *P < 0.05.
www.impactjournals.com/oncotarget
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Figure 6: TFP and BPD suppress the colony-forming ability of TNBC cells in a FOXO3-dependent manner. (A–B) (A)

BT549 cells were transfected with control-siRNA or FOXO3-siRNA for 48 h. The indicated proteins were detected by immunoblotting with
specific antibodies (Abs) against FOXO3 and GAPDH (loading control). (B) The transfected cells were treated with TFP, BPD or DMSO
(negative control) for 14 days and stained with crystal violet solution. Top (upper panels): the representative pictures of the assays are
shown. Bottom (lower panels): the numbers of colonies in the drug (TFP or BPD)-treated plates were compared with those of the DMSOtreated plates. The results are graphed as mean ± SEM numbers of cell colonies. The number of biological replicates is three. *P < 0.001
(drug vs DMSO). (C–D) (C) MDA-MB-231 cells were transfected with control-siRNA or FOXO3-siRNA, and the indicated proteins were
determined as described above. (D) The transfected cells were treated with TFP, BPD or DMSO (negative control) for 14 days, stained, and
the data are presented as described above.
www.impactjournals.com/oncotarget
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Figure 7: The aberrant expression of oncogenic survival proteins in TNBC tumors and the effect of TFP or BPD
on these proteins in TNBC cells. (A–B) Oncoprint analysis data of Akt2, Akt3, c-Myc (MYC), Kruppel-like factor 5 (KLF5), and

dopamine receptor D2 (DRD2) in TNBC patient samples are displayed. Data from the TCGA dataset containing molecular subtyping data
of 123 TNBC subtype (A) and 104 non-TNBC subtype (B) were extracted and used to generate an oncoprint plot using the cBioPortal
[39, 40]. Gene amplification (red bars) and mRNA copy number gain (pink bars) are shown. (C–D) BT549 cells were treated with a dose
response of TFP (C) or BPD (D) or DMSO control (denoted as 0 mM) for 24 hours, harvested, and fractionated for preparing cytoplasmic
(Cyt.) and nuclear (Nuc.) extracts. Equal amount of each fraction was analyzed by immunoblotting (IB) analysis with specific antibodies
as indicated. While a-Tubulin and GAPDH represent the loading controls of the Cyt. extract, Lamin A/C displays the loading control of
the Nuc. Extract.
www.impactjournals.com/oncotarget
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Figure 8: TFP and BPD significantly reduce the expression of oncogenic c-Myc, KLF5, and DRD2 in TNBC cells in a
FOXO3-dependent manner. (A) BT549 cells were transfected with control-siRNA or FOXO3-siRNA for 24 hours, transfected cells
were treated with TFP, BPD or DMSO (control) for 48 hours, harvested, and fractionated for preparing cytoplasmic and nuclear extracts.
Equal amount of each fraction was analyzed by immunoblotting (IB) analysis with the specific antibodies as indicated. Proteins β-Actin and
PARP1 represent the fractionation and loading controls of the cytosolic and nuclear fractions, respectively. (B) A diagram represents the
model for the FOXO3-dependent anticancer function of BPD and TFP. A schematic shows that BPD and TFP inhibit phosphor-Akt (pAkt)
and lead to FOXO3 translocation from the cytoplasm into the nucleus, where FOXO3 can upregulate the expression of p27Kip1, Bax, and
Bim proapoptotic proteins [17, 19, 41]. Moreover, BPD and TFP downregulate of the expression of c-Myc, KLF5 and DRD2 oncogenic
survival proteins in a FOXO3-dependent manner. As a result of this FOXO3-mediated apoptotic pathway, BPD and TFP promote TNBC
cell apoptosis.
www.impactjournals.com/oncotarget

42120

Oncotarget

It has been shown that Akt is aberrantly expressed
or constitutively activated in several cancers including
BCa [38]. Based on the relative phosphorylation status of
FOXO3 (Ser318/321) by Akt in cells treated with drugs,
we have developed a new cell-based screening system
for selecting small-molecule drugs that promote FOXO3
nuclear localization in BCa cells. Through this novel
screening system, we have identified and validated several
candidate drugs from an FDA-approved small-molecule
library. A key advantage of repurposing FDA-approved
drugs is that the toxicity profiles, pharmacokinetic, and
pharmacodynamic studies of these drugs have already
been approved by the FDA; thus, saving cost and time
for new drug development [29]. In addition, based on the
known activities of existing drugs, the mechanisms of
new actions of these drugs tend to be more predictable
and successful than those made of entirely unknown
compounds. For examples, while aspirin has been
previously used as an analgesic to relieve pain, it has
been recently shown to exert anti-platelet activity and is
rapidly being repurposed for preventing cardiovascular
diseases [42]. Before thalidomide was found to cause birth
defects, it was used to treat morning sickness in pregnant
women. When it was found to cause birth defects, it was
taken off the market. Later, through drug repurposing,
it became available again as a treatment for multiple
myeloma and leprosy. Milnacipran was initially used as
an antidepressant drug but it became one of three modern
drugs for treating fibromyalgia. Finally, thioridazine, an
anti-psychotic drug, was repurposed to selectively inhibit
the development of acute myeloid leukemia derived from
their CSC through antagonizing DRD2 [34].
We focused on two drugs (TFP and BPD) based
on their same target and similar clinical applications.
In agreement with our findings, TFP has been shown
to induce apoptosis in A549 lung cancer cell line that
is associated with downregulation of anti-apoptotic
Bcl-2 protein and upregulation of pro-apoptotic Bax
protein [43]. BPD has recently been shown to stimulate
the tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-mediated apoptosis in U251MG
glioblastoma cell line via upregulation of the expression
of death receptor 5 (DR5) [44]. Interestingly, FOXO3
can upregulate the expression of TRAIL in prostate
cancer cells [45], and FOXO3 may be essential for the
expression of DR5 in colon and live cancer cells [46, 47].
However, the roles and mechanisms of TFP and BPD in
suppressing TNBC cell survival and tumor development
are unknown and have not yet been explored. TFP and
BPD are known to be calmodulin antagonists, which have
been used clinically for treating psychotic disorders such
as schizophrenia and cardiac arrhythmia. Our current data
indicate a successful case of repurposing TFP and BPD for
treating TNBC. More importantly, we show that TFP and
BPD treatments promote suppression of the expression
of specific oncogenes (c-Myc, KLF5, and DRD2), which
www.impactjournals.com/oncotarget

are suggested to increase CSC-like populations in various
tumors [34, 48–50]. Also, our data suggest an essential
role of FOXO3 in TFP/BPD-induced downregulation of
these CSC-related oncogenic proteins, which is consistent
with our recent finding suggesting that FOXO3 may
be necessary for certain drug-mediated suppression of
the expression of markers (such as c-Myc and CD44)
exhibiting CSC characteristics in TNBC cells [51].
Moreover, TFP has a very similar chemical structure to
thioridazine, a CSC targeting drug that selectively inhibits
CSC [36], and both drugs exert similar pharmacological
effects when clinically treating psychotic disorders.
Collectively, our novel findings suggest that TFP and
BPD may become potential therapeutic drugs for TNBC,
although further investigation of this therapeutic concept
of targeting CSC in TNBC tumors with TFP and BPD (or
their analogs) is necessary to establish novel therapeutic
interventions in order to conquer malignant TNBC in the
future.

MATERIALS AND METHODS
Cell culture, cell lines, shRNA and siRNA
transfection
BT549 (human breast epithelial ductal carcinoma),
MDA-MB-231 (human breast invasive ductal carcinoma),
and MCF7 (human breast adenocarcinoma) cell lines were
obtained from the American Type Culture Collection, and
grown in DMEM/F12 supplemented with L-glutamine
(3%), penicilline/streptomycin (1%) and 10% fetal bovine
serum at 37oC in a humidified CO2 incubator (5% CO2).
Specific siRNA against FOXO3 (sc-37887) and controlsiRNA (sc-44231) were obtained from Santa Cruz
Biotechnology (SCBT) (Santa Cruz, CA). For transfection
with siRNA, cells were transfected with specific siRNA
or control siRNA as indicated by using DharmaFECT 1
transfection reagent (Thermo Scientific, Rockford, IL)
according to the manufacturer’s protocol.

Antibodies and reagents
TFP,
dimethylsulfoxide
(DMSO),
3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), and 3,3′,5,5′-Tetramethylbenzidine (TMB) were
purchased from Sigma (St. Louis, MO). Propidium
iodide (PI) was obtained from Fisher Scientific. BDP
and antibodies specific to FOXO3 (FKHRL1) N-16
(1:500 dilution) and H-144 (1:1000 dilution), p53-pS15
(1:1000 dilution), c-Myc (1:1000 dilution), a-Tubulin
(1:2000 dilution), PARP1 (1:1000 dilution), SOD2
(1:2000 dilution), and Lamin A/C (1:1000 dilution)
were purchased from SCBT. Antibody against phosphoH2AX Serine-139 (1:1000 dilution) was obtained from
Millipore (Billerica, MA). Specific antibodies against
phospho-FOXO3-S318/321 (#9465, 1:250 dilution),
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Akt-pS473 (1:1000 dilution), Akt (total, 1:1000 dilution),
and p27Kip1 (1:1000 dilution) were purchased from Cell
Signaling Technology (Danvers, MA). Antibodies against
FOXO3 (2071-1 and 3280-1) (1:1000 dilution) were
obtained from Epitomics (Burlingame, CA). Antibody
against β-Actin (1:3000 dilution) was purchased from
Sigma. Antibody against GAPDH (1:1000 dilution), Alexa
488- and Alexa 594-conjugated secondary antibodies
were obtained from Thermo-Fisher Scientific (Waltham,
MA). Goat anti-mouse IgG and goat anti-rabbit IgG
horseradish peroxidase-conjugated secondary antibodies
were purchased from Jackson ImmunoResearch (West
Grove, PA).

of nuclear FOXO3-positive cells was quantitated by
analyzing ~100 cells images randomly captured by
confocal microscopy with the Image J software (v.1.49).

Cytoplasmic and nuclear protein fractionation
Experiments were performed as described [19, 41].
Briefly, TNBC cells from various treatment conditions
were trypsinized, centrifuged, washed, re-suspended in
a cytoplasmic fractional buffer and incubated at 4°C for
30 min. The cell suspension was centrifuged at 10,000 rpm
for 30 min at 4°C and the supernatant was collected for
cytoplasmic fraction. The nuclear pellet was washed twice
with the washing buffer. The remaining pellet was resuspended with a nuclear fractional buffer and incubated
at 4°C for 30 min. The nuclear suspension was centrifuged
at 13,000 rpm for 30 min at 4°C, the supernatant was
collected for nuclear fraction. Protein in each fraction was
quantified as described [19, 41].

Cell-based ELISA assay
Cells (2 × 104/well in 100 µl medium) were seeded
into 96-well black microplates and incubated at 37oC for 24
hours in a CO2 incubator. Cells in each well were treated
separately with DMSO (negative control), LY294002
or Wortmannin (negative controls), and small-molecule
compounds (20 µg/ml final conc.) from the FDA-Approved
Drug Library (from Enzo Life Sciences International, Inc)
(totally 640 drugs, 80 drugs per 96-well plate) at 37°C and
5% CO2 for 24 hours. Then, cells were fixed and quenched
by adding 100 µl of 4% formaldehyde [in phosphatebuffered saline (PBS)] and 100 µl of 0.6% H2O2 (in PBS),
respectively. To determine the level of the phosphorylatedFOXO3-S318/321 in these cells, ELISA was performed
by treating cells with 100 µl of the blocking buffer [5%
bovine serum albumin (BSA) in Tris-buffered saline, 0.1%
Tween-20 (TBST)] for I hour. After washing, cells were
treated with 100 µl of primary antibody against phosphoFOXO3-S318/321 (1:250 dilution in TBST containing
2% BSA) at 4°C for overnight. After washing, cells were
treated with 100 µl of the anti-rabbit IgG horseradish
peroxidase-conjugated secondary antibody (1:1000 dilution
in TBST containing 2% BSA) at room temperature for 2
hours. After washing, cells were treated with 100 µl of
peroxidase substrate (TMB) for 15 minutes, followed by
adding 50 µl of ELISA stop solution (2N H2SO4). The
optical density of each well was measured by reading the
microplate using a microplate reader at 450 nm.

Immunoblotting analysis
For immunoblotting (Western blotting) analysis,
equal amount (20–50 mg) of each protein sample was
subjected to SDS-PAGE (8%–12%) and transferred
onto nitrocellulose membranes as described [19, 41, 51].
Briefly, membranes were blocked in 3% BSA in
TBST buffer and incubated for 1 hour with a primary
antibody. After three washes with TBST, membranes
were incubated for 1 hour with horseradish peroxidaseconjugated secondary antibodies (1:3000 or 1:5000
dilution). The immunoblots were visualized by enhanced
chemiluminescence as described [19, 41, 51].

MTT assays
TNBC cells (1 × 103/well) were seeded into
96-well plates and incubated at 37°C in a CO2 incubator
(5% CO2) overnight. TNBC cells were treated with
DMSO (control) and various doses of TFP or BPD as
indicated for 72 hours, followed by the addition of 20 µl
of MTT solution (5 mg/ml in phosphate buffer). After
incubation for 2 hours, the solution in each well was
removed, and then the blue crystalline precipitate in each
well was dissolved in DMSO (200 µl/well). The visible
absorbance at 545 nm of each well was quantified using
a microplate reader.

Immunofluorescence analysis
Experiments were essentially performed as
described [41, 51]. Briefly, BT549 cells were treated
with TFP (5 mM) or BPD (5 mM) or vehicle (DMSO) for
24 hours, fixed, and permeabilized. After blocking with
BSA, cells were incubated with a primary antibody against
FOXO3 (1:50 dilution) or p53-pS15 (1:100 dilution),
followed by Alexa 594 (red)-conjugated anti-rabbit (1:200
dilution) or Alexa 488 (green)-conjugated anti-mouse
(1:200 dilution) secondary antibody, respectively. After
counterstaining with DAPI, fluorescence images were
captured with a confocal microscope. The percentage
www.impactjournals.com/oncotarget

Annexin V staining fluorescence-activated cell
sorting (FACS) analysis
The percentage of cells that are undergoing
apoptosis was determined by using the FITC Annexin
V Apoptosis Detection Kit I (BD PharMingen) with
propiodium iodide according to the manufacturer’s
instructions. After treatment with various doses of TFP
or BPD or DMSO (negative control) or camptothecin
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(positive control) for 48 hours, cells were washed in PBS,
trypsinized, and resuspended in binding buffer [10 mM
Hepes/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2] at
a density of 1 × 106 cells/ml.
Afterwards, the cells were aliquoted into 5 ml
culture tubes (1 × 105 cells/tube) and incubated in binding
buffer containing 5 μl of FITC Annexin V and 5 μl of PI
for 15 min at 25°C in the dark. Cells were analyzed by
using a FACScan or FACSCalibur (BD Biosciences) at
the Institutional shared FACS Facility and the data were
analyzed by FlowJo or FCS 5 Express (De Novo Software,
CA). Ten thousand events were collected in each run. Each
data point represents the mean value from 3 independent
experiments. The error bars represent standard deviation
(SD), and the statistical test is the unpaired t-test.

with DMSO as control vehicle and TFP (5 μM) or BPD
(5 μM) for 14 days. Then, the colonies were washed
twice with PBS, fixed with 3.7% Paraformaldehyde, and
stained with 1% crystal violet solution in distilled water.
Experiments were performed three times.

Animal studies
To determine the antitumor effect of TFP and
BPD in vivo, female athymic (nu/nu) nude mice were
purchased from Charles River Laboratories, Inc.
(Wilmington, MA) and maintained aseptically in an
athymic animal room. For tumor-cell implantation,
MDA-MB-231 cells (in log-phase growth) were
harvested, washed with PBS, and re-suspended in PBS.
Then cells (5 × 106 in 0.1 ml PBS with 30% ECM gel)
were injected subcutaneously into the flank of each
mouse as described previously [51, 52]. When palpable
solid tumors were detected (approx. 100 mm3), each
group of mice was given an intravenous (i.v.) injection
(0.1 ml) of BPD or TFP (10 mg/kg-body weight/mouse)
three times per week at even intervals for five weeks.
The vehicle (DMSO) was used as a negative control
group. The tumor sizes were measured twice per week
with a Vernier caliper. Data are presented as means and
standard deviations (SD) of four mice in each group.
Mice were weighed twice per week as a measure of
overall systemic toxicity. All procedures were performed
in compliance with the guidelines and regulations of the
Institutional Animal Care and Use Committee (IACUC).
The IACUC has approved the experiments listed in the
Protocol number 21557 (Stanford’s Animal Welfare
Assurance Number: A3213-01).

Terminal deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL)
Experiments were performed as described [41].
Briefly, MDA-MB-231 cells were grown on glass
coverslips. After treatment with various doses of TFP or
BPD or DMSO (control) for 48 hours, cells were fixed
with 4% paraformaldehyde solution and permeabilized
with Triton X-100 (0.2%). For TUNEL assay, cellular
apoptosis assay was determined by enzymatic labeling of
DNA strand breaks with a TUNEL assay kit (the DeadEnd
Fluorometric TUNEL System, Promega) according to
the manufacturer’s instructions. Nuclei were stained
with DAPI (color was inverted to red). Merged images
(yellow) were considered as apoptotic cells and counted
under a confocal laser-scanning microscope (Leica SP2
AOBS). The samples include three biological replicates,
the error bars represent SD, and the statistical test is the
paired t-test.

Statistical analysis
All data are expressed as means and SD from at
least three determinations. The statistical significance of
difference in nuclear localization of proteins examined in
cells (by immunofluorescence) and in the percentage of
cell growth/survival (by MTT assay) or apoptotic nuclei
(by TUNEL assay) between two groups was analyzed with
two-sided unpaired Student’s t tests when the variances
were equal with Grahpad PRISM (Ver.6.07) statistical
software (San Diego, CA) or Excel (Microsoft Office). All
statistical tests were two-sided, and P values less than 0.05
were considered statistically significant.

DNA fragmentation assay
TNBC cells (2 × 107 per sample) were trypsinized,
lysed in the lysis buffer (10 mM Tris-HCl, 10 mM EDTA,
0.1% Triton-X 100, 0.1% SDS and pH 7.5) and incubated
on ice for 30 min. The lysates were digested with RNase
I followed by digestion with proteinase K. The DNA was
extracted by phenol-chloroform (1:1, v/v), precipitated
with 2 volumes of EtOH plus 10% NaAc (3 M, pH 5.2)
and then dissolved in distilled water. Equal amounts of
the extracted DNA (2 μg/lane) and size markers (1-kb
ladder) were subjected to electrophoresis on 2% agarose
gels, which were stained with ethidium bromide and
photographed.
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